*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Efficacy of Escitalopram versus Desvenlafaxine in Treatment of Depression: A Comparative Study from a Rural Tertiary Care Hospital

Author: , DR. SAIKIRAN PASUPULA, DR. MOUNICA YEDLAPALLI, DR. RAJESWARI PASUPULA, DR. SAKA MEGHANA, DR. SURESH KUMAR KOTA
Abstract: Introduction: Depression is one of the most common psychiatric disorders, and it is the second disorder causing a global health burden after cardiovascular disorders1. The etiology of Depression is multifactorial. Prevalence of Depression has been increasing daily, and early identification and management of Depression will result in a good prognosis. Pharmacotherapy plays a crucial role in relieving Depression, out of which SSRIs and SNRIs have promising results. Escitalopram and Desvenlafaxine are the two antidepressants that are widely used in the treatment of Depression among SSRI and SNRI, respectively. Aim and objectives: 1. To study the Efficacy of Escitalopram in the treatment of Depression. 2. To study the Efficacy of Desvenlafaxine in the treatment of Depression 3. To compare the Efficacy of Escitalopram and Desvenlafaxine in the treatment of Depression. Methodology: This Study was done at the Department of Psychiatry, Katuri medical college and Hospital , Guntur. The study sample includes sixty patients diagnosed with Depression. After prior ethical clearance, consent was taken from Patients attending to Psychiatry OPD. Individuals were screened with HAM –D (Hamilton Depression Scale), and diagnosis of Depression was con?rmed by ICD-10. All the patients were divided into two groups, and each group comprised of thirty patients. We gave adequate doses of Escitalopram and Desvenlafaxine, and the response was monitored using HAM D scores. Drug compliance and adverse drug reactions were taken after four weeks. Statistical analysis was done with EPI INFO 7.0 and Microsoft Excel software. Results: Among the two groups, it was observed that there is an equal reduction in HAM –D scores (more than 50%) after four weeks of drug initiation. There are no significant side effects observed among the two groups, except two individuals with Desvenlafaxine reported denovo hypertension for which the drug was discontinued. In the Escitalopram group, nine individuals complained of insomnia, and two individuals complained of hypersomnia, which was relieved spontaneously after a few days of treatment; seven patients reported Gastritis, which was treated with antacids. Conclusion: Desvenlafaxine and Escitalopram are equally efficacious in relieving the symptoms of depression, out of which somatic symptoms are greatly reduced with Desvenlafaxine. More such studies at multicentre levels are needed for better generalization of the results.
Keyword: Depression, Escitalopram, Desvenlafaxine
DOI: https://doi.org/10.31838/ijpr/2021.13.01.176
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free